On March 23, 2021, National Institute of Allergy and Infectious Diseases (NIAID) released a statement on AstraZenaca’s COVID-19 vaccine information which stated, “[l]ate Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.” The statement continued, “The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.”
On this news, AstraZenaca’s American Depositary Share (ADS) price fell in pre-market trading, damaging investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.